Key facts
- This page summarizes Richard Chester Wright's Form 4 filing for Ensysce Biosciences, Inc. (ENSC).
- 5 reported transactions and 5 derivative rows are listed below.
- Accepted by SEC: 02 Jul 2021, 18:08.
Richard Chester Wright - 30 Jun 2021 Form 4 Insider Report for Ensysce Biosciences, Inc. (ENSC)
- Reporting relationship
- Chief Business Officer
- Issuer ticker
- ENSC
- Reported as of
- 30 Jun 2021
- Net transaction value
- $0
- Reporting owner signature
- /s/ Richard Wright
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Richard Chester Wright filed Form 4 for Ensysce Biosciences, Inc. (ENSC) on 02 Jul 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ENSC
transaction
Derivative
Stock Option
Award
- Transaction value
- Shares
- +49,975
- Change %
- Price
- Shares after
- 49,975
- Date
- 30 Jun 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 49,975
- Exercise price
- $3.21
- Footnotes
- F1
ENSC
transaction
Derivative
Stock Option
Award
- Transaction value
- Shares
- +65,850
- Change %
- Price
- Shares after
- 65,850
- Date
- 30 Jun 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 65,850
- Exercise price
- $1.83
- Footnotes
- F1
ENSC
transaction
Derivative
Stock Option
Award
- Transaction value
- Shares
- +263,400
- Change %
- Price
- Shares after
- 263,400
- Date
- 30 Jun 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 263,400
- Exercise price
- $1.83
- Footnotes
- F1
ENSC
transaction
Derivative
Stock Option
Award
- Transaction value
- Shares
- +19,755
- Change %
- Price
- Shares after
- 19,755
- Date
- 30 Jun 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 19,755
- Exercise price
- $2.59
- Footnotes
- F1
ENSC
transaction
Derivative
Stock Option
Award
- Transaction value
- Shares
- +987,750
- Change %
- Price
- Shares after
- 987,750
- Date
- 30 Jun 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 987,750
- Exercise price
- $2.59
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
On June 30, 2021, pursuant to that certain Agreement and Plan of Merger dated January 31, 2021 (the "Merger Agreement") among Ensysce Biosciences, Inc. (f/k/a Leisure Acquisition Corp.) (the "Issuer"), EB Merger Sub, Inc., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer ("Merger Sub"), and Ensysce Biosciences, Inc., a Delaware corporation ("Ensysce"), Merger Sub merged with and into Ensysce (the "Merger"), with Ensysce surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a "Derivative Security") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement.